Phreesia, Inc. (NYSE:PHR) Reports Strong Revenue Growth Despite EPS Miss

Font: Financial Modeling Prep  • Mar 31, 2026

• Revenue Growth: Phreesia's total revenue for Q4 reached $127.1 million, a 16% year-over-year increase, surpassing estimates.
• Operational Efficiency: The company achieved a positive GAAP net income of $2.3 million and generated $50 million in free cash flow.
• Financial Stability: With a quick and current ratio of 2.44 and a debt-to-equity ratio of 0.01, Phreesia maintains strong liquidity and low leverage.

(NYSE:PHR) is a healthcare technology company that provides patient intake management solutions. It helps healthcare providers streamline their operations and improve patient experiences. The company competes with other healthcare technology firms like Cerner and Allscripts. On March 30, 2026, Phreesia reported earnings per share (EPS) of $0.02, which was below the estimated $0.06. However, the company generated revenue of approximately $127.1 million, slightly surpassing the estimated $126.8 million.

Despite the lower-than-expected EPS, Phreesia achieved several financial milestones for the fiscal year ending January 31, 2026. The company reported a positive GAAP net income of $2.3 million and exceeded $100 million in Adjusted EBITDA. Additionally, Phreesia generated $50 million in free cash flow, with net cash from operating activities reaching $78.8 million. These achievements reflect the company's strong financial performance and operational efficiency.

Phreesia's total revenue for the fiscal fourth quarter was $127.1 million, marking a 16% increase compared to the previous year. The average number of healthcare services clients (AHSCs) rose by 7% year-over-year to 4,658, while total revenue per AHSC increased by 8% to $27,279. This growth indicates the company's ability to expand its client base and increase revenue per client, contributing to its overall financial success.

Despite these positive developments, Phreesia's shares experienced a decline of 5.8%, closing at $10.98 on Friday. Mizuho analyst Steven Valiquette maintained an Outperform rating for Phreesia but adjusted the price target from $22 to $19 on March 24, 2026. The company's stock opened at $11.88 on Monday, showing a 0.9% increase. Phreesia's stock has experienced a 52-week low of $10.75 and a high of $32.76, reflecting its volatility in the market.

Phreesia's financial health is supported by a quick and current ratio of 2.44, with a debt-to-equity ratio of 0.01. The company's market capitalization stands at $716 million and a beta of 0.67. These metrics indicate that Phreesia has a strong liquidity position and low leverage, which can help it navigate market fluctuations and invest in future growth opportunities.